Assenagon Asset Management
FATE icon

Assenagon Asset Management’s Fate Therapeutics FATE Stock Holding History

Assenagon Asset Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$394K Sell
145,838
-44,414
-23% -$82.2K ﹤0.01% 1093
2026
Q1 		$228K Buy
190,252
+41,599
+28% +$50.6K ﹤0.01% 1071
2025
Q4 		$146K Buy
148,653
+2,815
+2% +$3.38K ﹤0.01% 1127
2025
Q3 		$184K Sell
145,838
-66,504
-31% -$71.7K ﹤0.01% 1135
2025
Q2 		$238K Sell
212,342
-90,557
-30% -$105K ﹤0.01% 1104
2025
Q1 		$239K Sell
302,899
-69,608
-19% -$85.3K ﹤0.01% 1094
2024
Q4 		$615K Sell
372,507
-2,061,691
-85% -$5.19M ﹤0.01% 1172
2024
Q3 		$8.52M Sell
2,434,198
-140,505
-5% -$547K 0.02% 575
2024
Q2 		$8.45M Buy
2,574,703
+26,399
+1% +$116K 0.02% 476
2024
Q1 		$18.7M Buy
2,548,304
+2,385,207
+1,462% +$14.8M 0.04% 296
2023
Q4 		$610K Sell
163,097
-217,640
-57% -$514K ﹤0.01% 1221
2023
Q3 		$807K Buy
380,737
+280,895
+281% +$931K ﹤0.01% 1096
2023
Q2 		$475K Buy
+99,842
New +$551K ﹤0.01% 1139
2022
Q4 		– Sell
-14,583
Closed -$327K – 1387
2022
Q3 		$327K Sell
14,583
-21
-0.1% -$607 ﹤0.01% 1184
2022
Q2 		$362K Sell
14,604
-6
-0% -$166 ﹤0.01% 1291
2022
Q1 		$566K Sell
14,610
-5
-0% -$194 ﹤0.01% 1183
2021
Q4 		$855K Sell
14,615
-109,893
-88% -$6.23M ﹤0.01% 1079
2021
Q3 		$7.38M Sell
124,508
-292,850
-70% -$23M 0.02% 334
2021
Q2 		$36.2M Buy
+417,358
New +$33.6M 0.12% 148
2021
Q1 		– Sell
-25,323
Closed -$2.3M – 1232
2020
Q4 		$2.3M Sell
25,323
-57,776
-70% -$3.59M 0.01% 493
2020
Q3 		$3.32M Buy
83,099
+42,721
+106% +$1.49M 0.02% 466
2020
Q2 		$1.39M Buy
+40,378
New +$1.2M 0.01% 705

Other funds holding FATE

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
NAM
NorthCrest Asset Manangement Plymouth, Minnesota $3.89B AUM 40.33% 1-Year Est. Return
WP
Westmount Partners Los Angeles, California $457M AUM 31.05% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
HNB
Hilltop National Bank Casper, Wyoming $468M AUM 36.09% 1-Year Est. Return

Assenagon Asset Management's FATE Position: Q2 2026 in Review

Assenagon Asset Management reduced its Fate Therapeutics (FATE) stake by 23% in Q2 2026, selling an estimated $82.2K and leaving 145,838 shares worth $394K. The position accounts for ﹤0.01% of the portfolio, ranked #1093.

Assenagon Asset Management first reported a position in FATE in Q2 2020 and has held it in 22 quarters since. The position peaked at $36.2M in Q2 2021. 10 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Assenagon Asset Management held 145,838 shares of Fate Therapeutics worth $394K as of Q2 2026.
  • Assenagon Asset Management sold 44,414 Fate Therapeutics shares in Q2 2026, an estimated $82.2K.
  • Fate Therapeutics made up ﹤0.01% of Assenagon Asset Management's portfolio in Q2 2026, its #1093 holding.
  • Assenagon Asset Management first reported a position in Fate Therapeutics in Q2 2020 and has held it in 22 quarters since.
  • Assenagon Asset Management's Fate Therapeutics position peaked at $36.2M in Q2 2021.
  • 10 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.